Originally published In Press as doi:10.1074/jbc.M109414200 on February 13, 2002
J. Biol. Chem., Vol. 277, Issue 17, 14612-14621, April 26, 2002
Divergent Regulation of the Growth-promoting Gene
IEX-1 by the p53 Tumor Suppressor and Sp1*
Hee-Jeong
Im
,
Mark R.
Pittelkow§, and
Rajiv
Kumar
¶
From the Departments of
Internal Medicine,
Biochemistry, and Molecular Biology and § Dermatology,
Mayo Clinic and Foundation, Rochester, Minnesota 55905
Received for publication, September 28, 2001, and in revised form, February 13, 2002
 |
ABSTRACT |
IEX-1, a recently discovered early
response gene, regulates cell growth and apoptosis. IEX-1
gene expression is regulated by a variety of factors such as
x-irradiation, ultraviolet radiation, steroids, growth factors, and
inflammatory stimuli. By systematic examination of the
IEX-1 promoter, we show that IEX-1 gene
expression is controlled by multiple conserved gene regulatory elements
and that IEX-1 is a downstream target of the p53 tumor
suppressor and Sp1. In addition, p300, Sox, nuclear factor-
B, and
AP4 appear to be modulators of IEX-1 gene expression to a
lesser degree. We found that there is at least one Sp1 element that
functions as an activator and contributes to high basal transcriptional levels of the IEX-1 gene. We demonstrate the presence of a
p53 response element that represses IEX-1 promoter activity
in HaCaT keratinocytes, indicating that Sp1 and p53 have opposite
effects on IEX-1 gene expression. We conclude that
IEX-1 expression in cells is regulated by the p53 tumor
suppressor and Sp1, thus providing a direct mechanism for control of
cell proliferation.
 |
INTRODUCTION |
Expression of immediate-early genes is rapidly and transiently
induced in response to growth factors and other extracellular signals.
Genes unregulated during growth factor stimulation include nuclear proteins (e.g. c-Fos, c-Jun, c-Myc, zinc finger
proteins, and nuclear hormone receptors), secretory molecules
(e.g. cytokine-related factors), and components of the
cytoskeleton and extracellular matrix. Nuclear factors encoded by
immediate-early genes regulate expression of other genes that are
required for cell cycle progression toward the G1/S phase
transition (1). IEX-1
(immediate-early response factor X)
represents a recently characterized member of the immediate-early gene
family that may be critical for control of cell proliferation in
several cell types.
IEX-1 (also known as Dif-1 and PRG1),
the human ortholog of murine gly96, was first identified in
human squamous carcinoma cells as a radiation-inducible immediate-early
gene (2-5). The IEX-1 gene encodes a 17-kDa, 156-amino acid
protein that undergoes post-translational modification by glycosylation
to yield a product of 27-29 kDa (5). Apart from the induction of
IEX-1 in x-irradiated human tumor cells (5), this gene is
known to be regulated at the mRNA level by ultraviolet B radiation
(6), growth factors such as epidermal growth factor (6, 9), steroid
hormones such as
1,25-dihydroxyvitamin D3 (7), and
inflammatory stimuli such as lipopolysaccharide and ceramide (8).
Studies from our laboratory (6, 7) and others (9) suggest that IEX-1
plays a critical role in the control of keratinocyte cell growth and apoptosis. Consistent with this concept, IEX-1 is a nuclear protein whose cellular location is altered by steroid hormones such as
1,25-dihydroxyvitamin D3 (7) that influence cell growth
and differentiation. Recent reports have shown that disruption of IEX-1 expression by hammerhead ribozymes specifically
reduces growth rate and influences cell cycle progression in 293 cells (10). In addition, 293 cells stably transfected with hammerhead concatameric ribozyme expression constructs are much less sensitive to
Fas/CDE95-mediated apoptosis or the anticancer drugs etoposide and
doxorubicin. Hence, IEX-1 may promote cell proliferation when growth
factor conditions are favorable and facilitate apoptosis through death receptor activation under unfavorable conditions (10).
Comparable results have been obtained in our laboratory using a
keratinocyte cell system (11). Forced expression of IEX-1
significantly increases the growth rate of keratinocytes under basal
conditions and increases the rate of apoptosis when cells are subjected
to stress (11).
Because IEX-1 plays an important role in cell growth and apoptosis, the
molecular mechanisms by which the IEX-1 gene is regulated require further investigation. Several regulatory factors involved in
the transcriptional control of the IEX-1 gene such as p53
(12, 13) and NF-
B1 (12,
14) have been identified. The tumor suppressor p53 is a crucial
regulator of cell cycle progression, apoptosis in DNA-damaged cells,
and maintenance of genomic stability (15, 16). The development of a
wide range of malignant tumors is mediated by the mutational
inactivation of p53 (17). Similar to the p21Waf1 gene
(18), which is a well characterized p53 target gene that is directly
involved in p53-dependent G1 cell cycle arrest
(19), there is a p53-binding site in the human IEX-1
promoter. Schafer et al. (13) demonstrated that the
p53-binding site in the p22 (IEX-1/Dif-2)
promoter mediates transcriptional activation of p22 in a
fashion similar to that observed for the p21Waf1 gene in HeLa
and Hep3B cells. In this study, we have systematically examined the
transcriptional elements that regulate IEX-1 gene expression
in HaCaT keratinocytes. We demonstrate that the p53-binding site
modulates the promoter activity of the IEX-1 gene in
keratinocytes, but our evidence indicates that p53 functions as a
transcriptional repressor rather than an activator of IEX-1.
We also found that transcription factor Sp1, but not Sp3, is a
transcriptional activator of the IEX-1 gene. We propose that
p53 suppresses Sp1-dependent activation of IEX-1
gene expression in keratinocytes.
 |
EXPERIMENTAL PROCEDURES |
Cell Cultures and Transient Transfection--
Human primary
keratinocytes were isolated from neonatal foreskin specimens, and cell
cultures were maintained in an undifferentiated replicative state by
growth and passage at subconfluence in complete serum-free MCDB153
medium as previously described (20). Complete MCDB153 medium contains
0.1 mM calcium supplemented with 0.2% (v/v) bovine
pituitary extract, 10 ng/ml epidermal growth factor, and 5 µg/ml
insulin. Standard MCDB153 medium was prepared by excluding bovine
pituitary extract, epidermal growth factor, and insulin from the
culture medium. Cultures of autonomously growing human keratinocytes
were prepared by washing cells propagated in complete medium with
standard medium and refeeding subconfluent cell cultures with standard
medium. HaCaT cells were maintained in Dulbecco's modified Eagle's
medium (Invitrogen) supplemented with 10% fetal calf serum as
described (21). For transfection, cells were plated 24 h prior to
transfection at a density of 1 × 106 cells/plate in
six-well plates and transiently transfected with 1 µg of
IEX-1 promoter/firefly luciferase reporter gene constructs using 6 µl of FuGENE 6 transfection reagent (Roche Molecular
Biochemicals). The Renilla luciferase construct pRL-TK (100 ng; Promega) was included as an internal control for transfection
efficiency. Cells were harvested 24 h post-transfection, and
luciferase activity was assayed by the Dual-Luciferase reporter assay
system using a luminometer (Turner Designs, Sunnyvale, CA) following
the accompanying instructions. All transfection experiments were
repeated four or more times in duplicate, utilizing plasmids that were
independently prepared at least twice.
Deletion and Site-directed Mutagenesis--
The IEX-1
promoter construct
1419pIEX-1 fused into the
chloramphenicol acetyltransferase report gene was kindly provided by
Dr. Mira O. Jung (Georgetown University Medical Center, Washington, D. C.). The
1419pIEX-1 DNA fragment was fused into the
firefly luciferase reporter gene plasmid (pGL3-Basic) at the
KpnI and NheI restriction enzyme sites. For
deletion mutagenesis,
575pIEX-1,
279pIEX-1,
200pIEX-1,
150pIEX-1,
110pIEX-1, and
70pIEX-1 PCR products were
generated with sense and antisense primers containing appropriate
restriction enzyme sites and template
1419pIEX-1 DNA.
These PCR products were cloned into the pCR2.1-TOPO cloning vector
using the TOPO TA cloning kit (Invitrogen), followed by subcloning into
the promoterless pGL3-Basic plasmid at the KpnI and
NheI restriction enzyme sites. Site-directed mutagenesis was performed using the QuikChangeTM site-directed mutagenesis
kit (Stratagene). In brief, sense- and antisense-oriented primers
complementary to each other and bearing SalI enzyme
restriction sites were mixed with the template plasmid for generation
of PCR products. This was followed by DpnI restriction
enzyme digestion (37 °C for 3 h) to remove the template plasmid. The unmethylated PCR product was transformed into
Escherichia coli XL1-Blue competent cells (Stratagene) and
selected on ampicillin (100 µg/ml)-agar plates. The DNA sequences of
all constructs were verified by KpnI/NheI
(IEX-1 promoter deletion constructs) or SalI
(site-directed mutagenesis) restriction enzyme digestion, followed by
dideoxy DNA sequencing using an automated sequencer and the dideoxy
sequencing method of Sanger et al. (22). The PCR primers
used for the promoter deletion constructs and site-directed mutagenesis
are listed in Table I.
View this table:
[in this window]
[in a new window]
|
Table I
PCR primers used for the deletion and site-directed mutagenesis of the
IEX-1 promoter
The primer sequences are from 5' to 3'. The core response elements
replaced by SalI restriction enzyme sites are indicated in
boldface, italic, underlined letters.
|
|
Construction of Protein Expression Vectors--
Reverse
transcription-PCR for the construction of Sox18 (Sry-like
HMG box-containing transcription factor) cDNA was
performed using the ThermoScript reverse transcription-PCR system
(Invitrogen) as described by the manufacturer. The Sox18 cDNA
obtained by reverse transcription-PCR was gel-purified and cloned into
the pCR2.1-TOPO cloning vector using the TOPO TA cloning kit following
the instructions provided by the manufacturer. The coding sequence in
the pCR2.1-TOPO cloning vector was separated from the vector DNA by
EcoRI restriction enzyme digestion, followed by agarose gel
purification of the cDNA fragment. The purified cDNA was
subcloned into the EcoRI restriction enzyme site of the
pcDNA3 expression vector (Invitrogen). The resulting mammalian
expression plasmid was verified by restriction enzyme digestion, and
the orientation of the insert was confirmed by DNA sequencing. The
primer set used for Sox18 reverse transcription-PCR is as follows:
Sox18-f, 5'-CAT CAG ACC TCC GTA CTT GGC TTT GCA GTG-3'; and Sox18-r,
5'-TTA GCT TCT TCA CCA CCA ATC CTG GCA GAG-3'. Other Sox cDNAs
(Sox5, Sox6, and Sox9) were provided by Dr. Veronique Lefebvre
(University of Texas, Houston, TX). pCMV-Sp1 and pCMV-Sp3 expression vectors were provided by Dr. Andre J. van Wijnen (University of Massachusetts Medical School, Worcester, MA), and a pCMV-p300 expression vector was provided by Dr. Ralf Janknecht (Mayo Clinic, Rochester, MN). Other expression vectors for p53 and I
B
, a
dominant-negative inhibitor of NF-
B, were purchased from CLONTECH.
Northern Analysis--
Poly(A)+ RNA isolation,
Northern blotting, and hybridization were carried out using established
methods as previously described (23). Appropriate cDNA probes were
radiolabeled by random priming with [32P]dCTP for
hybridization purposes.
In Vitro Translation and Electrophoretic Mobility Shift
Assays--
Electrophoretic mobility shift assays were performed as
described previously (23). In vitro translation was
conducted using the TNT Quick coupled transcription/translation system
(Promega) as described by the manufacturer. Briefly, in
vitro translated protein was incubated with 1 ng of
32P-labeled double-stranded oligonucleotides probe in 10 µl of reaction solution containing 10 mM Tris (pH 7.5),
5% glycerol, 1 mM EDTA (pH 7.1), 50 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, and 0.1 mg/ml
poly(dI-dC). After incubation at 22 °C for 30 min, the mixture was
analyzed on 5% nondenaturing polyacrylamide gels in 0.5× Tris borate/EDTA buffer at room temperature, and bands were
visualized using a Storm 840 PhosphorImager (Molecular Dynamics, Inc.,
Sunnyvale, CA). The double-stranded oligonucleotides used as probes are
listed in Table II.
View this table:
[in this window]
[in a new window]
|
Table II
Double-stranded synthetic oligonucleotides used as probes in
electrophoretic mobility shift assays
The oligonucleotide sequences are from 5' to 3'. The mutated base pairs
(replaced by SalI sites) are indicated by boldface lowercase
letters.
|
|
 |
RESULTS |
Delineation of Regulatory Elements in the Promoter of the Human
IEX-1 Gene--
To understand the cell growth regulatory mechanisms
that control expression of the IEX-1 gene, we initiated
studies to define the basal promoter, cis-acting elements,
and cognate factors mediating IEX-1 gene transcription. A
genomic DNA segment spanning ~1.4 kb of the 5'-upstream region of the
human IEX-1 promoter has previously been cloned (5).
The 5'-region of the human IEX-1 gene contains multiple
putative recognition motifs for distinct classes of transcription factors and a TATA box sequence located 25 bp upstream from the transcription initiation site (Fig. 1).
The multiplicity of consensus elements in the IEX-1 promoter
may provide many combinatorial control to regulate IEX-1
gene transcription.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 1.
Structural features of 5'-flanking sequences
(nucleotides 1419 to +1) of the human
IEX-1 gene. Nucleotide +1 corresponds to
the translation start site (ATG). The multiple putative
cis-acting elements in the upstream sequences of the human
IEX-1 promoter are illustrated. Putative Sp1 and p53
response elements are shown as gray and black
boxes, respectively. The deletion sites for the IEX-1
promoter deletion constructs ( 1419, 575, 279, 200, 150,
110, and 70) used in this study to show the presence or absence of
the putative cis-acting elements in the particular construct
are indicated at the top. A TATA box is located 25 bp upstream from the
transcription initiation site (TIS). SRE, serum
response element; RE, response element; HRE,
hormone response element; USF, upstream stimulatory
factor.
|
|
To address the contribution of distinct promoter segments to
IEX-1 gene transcription, we transfected a series of
IEX-1 promoter deletion constructs fused to the firefly
luciferase reporter gene into HaCaT and primary keratinocyte cells. Our
results show that deletion of the promoter to bp
279 did not
significantly affect transcriptional levels (Fig.
2). Subsequent deletion of the segment between bp
279 and
200 increased promoter activity by 2-3-fold in
HaCaT cells, and this level of promoter activity was 50-200-fold higher than that of a promoterless reporter gene construct, pGL3-Basic. A relatively high basal level of transcription was retained with the
150 promoter deletion construct. Deletion of promoter sequences between bp
150 and
110 strongly reduced transcription by 3-fold. Further deletion of the promoter from bp
110 to
70 further reduced transcriptional activity, which remained severalfold higher than the
background promoter activity observed with the promoterless luciferase
construct (Fig. 2). Therefore, we conclude that the 5'-region of the
IEX-1 gene contains a potent basal promoter region (bp
279
to +1) that encompasses a repressor element between bp
279 and
200.
In addition, at least one strong activator region is noted between bp
150 and
110, and some modest transcriptional activity is conferred
by a proximal region (bp
110 to +1). Similar results were obtained
when the IEX-1 promoter deletion constructs were transiently
transfected into human primary keratinocyte cells.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2.
Identification of the minimal functional
IEX-1 promoter (bp 279 to +1),
which contains a repressor element between bp
279 and 200 of the
IEX-1 promoter. A, schematic
representation of a series of 5'-deletion constructs of the human
IEX-1 gene promoter fused to the recombinant luciferase
(Luc) reporter gene. B, summary results of
luciferase activity. Each deletion construct was transiently
transfected into HaCaT (white bars) and primary keratinocyte
(gray bars) cells. The cells were harvested 24 h later,
and a luciferase reporter assay was performed. pGL3-Basic (which is
promoterless) and pGL3-Control (containing the SV40 enhancer and
promoter) were used as negative and positive controls, respectively.
Transfection efficiencies were normalized to the Renilla
luciferase activity from the cotransfected internal control plasmid
(pRL-TK). The activities of the luciferase reporter are expressed as
-fold relative to the activity of the promoterless pGL3-Basic vector
(which was assigned an activity value of 1.0). The data shown are means
of three independent experiments in duplicates, with at least two
different plasmid preparations.
|
|
Divergent Control of IEX-1 Gene Transcription Involves Consensus
Recognition Elements for p53 and Sp1 Factors--
To assess whether
consensus elements for distinct classes of gene regulatory factors are
capable of modulating IEX-1 gene expression, we used
site-directed mutagenesis to incorporate a systematic series of point
mutations into reporter gene constructs driven by the minimal
functional IEX-1 promoter (bp
279 to +1). Site-directed
mutagenesis of regulatory response elements of the IEX-1
promoter was performed by replacing the core response element sequences
with SalI restriction enzyme sites (see "Experimental Procedures"). We performed transient transfection analyses with this
panel of mutant promoter/reporter gene constructs in HaCaT cells. One
of the most striking results is that mutation of a putative recognition
motif for the p53 tumor suppressor protein located in the
256/
237
region increased transcription by 3-fold (Fig.
3). This result suggests that the
putative p53 motif represents a bona fide cis-acting element
that apparently plays an important role as a transcriptional repressor.
On the other hand, mutation of the Sp1/GC box consensus motif located
in the
63/
55 region decreased basal promoter activity by at least
4-fold as shown in mutant constructs mSp1/
575, mSp1/
279, and
mSp1/
150 (Fig. 3). Slight modifications of transcriptional effects
were observed by mutating putative elements for p300 (mp300/
200;
i.e. ~40% reduction), Sox (mSox/
200; i.e.
30% reduction), NF-
B (mNF-kB/
200 and mNF-kB/
150;
i.e. 30% reduction), and AP4 (mAP4/
200; i.e. 10~15% reduction) (Fig. 3). However, forced expression of p300, various Sox proteins (Sox5, Sox6, Sox9, and Sox18), and the NF-
B dominant-negative inhibitor I
B
showed no significant increase in
promoter activity (data not shown). These data indicate that there are
at least two distinct negative and positive cis-acting elements in the human IEX-1 promoter, which coincide with
consensus recognition motifs for p53 and Sp1, respectively. Expression
of the human IEX-1 gene appears to be regulated by these two
regulators. In addition, although individual mutation of the putative
elements in the IEX-1 promoter region was not sufficient to
show dramatic modification of promoter activity, promoter deletion
analysis indicated that the combination of these putative elements may exert their effect on overall IEX-1 transcriptional
activity.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 3.
Site-directed mutagenesis of the
multiple putative cis-acting sites in the human
IEX-1 5'-flanking promoter region. The numbers at
the ends of the mutated cis-acting elements indicate the
template plasmid construct. Each set of site-directed mutants from
different templates was transfected into HaCaT cells, and the relative
luciferase activity is distinguished by shadowed bars
(black, dark gray, medium gray,
light gray, and white) according to the templates
utilized for the mutations. The luciferase reporter activities were
normalized to the activity of the pGL3-Basic plasmid. For detailed
experimental conditions, see "Experimental Procedures." Mutation of
the Sp1 cis-acting element using different templates
(mSp1/ 575, mSp1/ 279, and mSp1/ 150) was carried out by replacing
the core sequence of the Sp1 cis-acting element present
between bp 70 to 50 with a SalI restriction enzyme
site.
|
|
Apart from these findings, which indicate a role for p53 and Sp1 in the
transcriptional control of the human IEX-1 gene, we also
mutated a putative helix-loop-helix/E box located in the
185/
175 region (mE-box/
279). We observed that this mutation up-regulated IEX-1 promoter activity by at least 3-fold,
thus raising the possibility of a role for this inhibitory protein in
the regulation of IEX-1 gene expression (Fig. 3).
Interestingly, however, deletion of the entire E box region (from bp
200 to
150) appeared to be quantitatively neutral for promoter
activity (Fig. 2). This finding suggests that a compensatory positively acting factor, which is distinct from the HLH/E box protein, may functionally interact with the
200/
150 segment of the
IEX-1 promoter region. In the remainder of our studies, we
focused our investigation on the characterization of p53- and
Sp1-related regulatory mechanisms.
The GC Box-binding Protein Sp1, but Not Sp3, Enhances Basal Levels
of IEX-1 Gene Transcription--
The
110 promoter deletion construct
retains significant promoter activity and contains a perfect Sp1
consensus motif. To determine the specific role of Sp1 in the
transcriptional regulation of IEX-1 gene expression, we
cotransfected Sp1 or Sp3 expression vectors with IEX-1
promoter plasmids and then analyzed the effect on IEX-1
promoter activity. We found that Sp1, but not Sp3, selectively enhanced
reporter gene expression (Fig.
4A) and that coexpression of
Sp3 and Sp1 did not decrease Sp1-dependent enhancement. The enhancement of IEX-1 promoter activity by Sp1 was observed
even in the
110pIEX-1 deletion construct, in which most of
the putative elements have been deleted, except for the AP4 and Sp1
motifs. Coexpression of Sp3 and Sp1 also did not show synergistic
effects. These results indicate that Sp3 does not function as a
dominant-negative inhibitor of Sp1 function, as a cofactor, or as a
synergistic enhancer as has been observed for other genes such as the
cell growth-regulated dihydrofolate reductase and opioid receptor genes (24, 25). Our results show that Sp1 stimulated IEX-1
promoter activity in a concentration-dependent manner (Fig.
4B), and this transcriptional enhancement was detected with
the
279,
200, and
150 promoter deletion constructs. On the other
hand, increased amounts of the pcDNA3.1 vector, which contains a
cytomegalovirus promoter, failed to enhance the promoter activity of
these deletion constructs (data not shown). We conclude that Sp1 is a
rate-limiting element for IEX-1 promoter activity and
functions via a site from bp
63 to
55 in the IEX-1
promoter region. Sp1 site-directed mutation experiments demonstrated
that this Sp1 mutation not only decreased promoter activity (Fig. 3),
but also abolished Sp1-dependent activation of
IEX-1 promoter activity (Fig. 4C). The results in Fig. 4 indicate that Sp1 is an important transactivator of
IEX-1 gene transcription.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
Identification of a response element
for Sp1 and its effect on the transcriptional activity of the
IEX-1 promoter in HaCaT cells. A,
relative luciferase activities after transient cotransfection with
pCMV-Sp1 (gray bars), the related protein Sp3 (black
bars), and pCMV-Sp1/Sp3 (hatched bars) were analyzed
after a 24-h incubation at 37 °C in 10% CO2.
B, concentration-dependent enhancement of
IEX-1 promoter activity by Sp1. Each IEX-1
promoter deletion construct was cotransfected with a gradually
increased amount of the pCMV-Sp1 vector (10 ng, 100 ng, 500 ng, 1 µg,
and 2 µg). C, Sp1 effect on the Sp1 response element
between bp 70 and 50 in the IEX-1 promoter region. Sp1
site-directed mutants and the template wild-type promoter deletion
constructs were compared after transient transfection in the presence
(gray bars) and absence (white bars) of pCMV-Sp1.
For all experiments, pGL3-Basic (which is promoterless) and
pGL3-Control (containing the SV40 enhancer and promoter) were used as
negative and positive controls, respectively. Transfection efficiencies
were normalized to the Renilla luciferase activity from the
cotransfected internal control plasmid (pRL-TK). The activities of the
luciferase reporter are expressed as -fold relative to the activity of
pGL3-Basic (which was assigned an activity value of 1.0). The data
shown are means of three independent experiments in duplicates, with at
least two different plasmid preparations. For detailed experimental
conditions, see "Experimental Procedures."
|
|
Identification of a Response Element for the p53 Tumor Suppressor
Protein in the Human IEX-1 Gene--
The inherent inhibitory function
of the
279/
200 region, which contains a putative p53 recognition
motif, is indicated by transient transfection analyses demonstrating
that both deletion of this 79-bp DNA segment (Fig. 2) and mutation of
the p53 consensus motif (Fig. 3) significantly up-regulated
IEX-1 promoter activity. To test the direct role of p53 in
repression of IEX-1 gene transcription, we performed
cotransfection experiments with a series of IEX-1 promoter
deletion constructs and a wild-type p53 expression vector.
We found that the
1419,
575, and
279 promoter deletion constructs
were all responsive to forced expression of p53, as reflected by a
2-fold decrease in transcriptional activity (Fig.
5). In contrast, the
200,
150,
110,
and
70 promoter deletion constructs, which lack the p53 motif, were
not responsive (Fig. 5). Furthermore, the p53 site-directed mutant,
which exhibited increased basal promoter activity, was not repressed by
forced expression of p53. Taken together, these data establish that p53
inhibits IEX-1 promoter activity via a functional p53
response element located in the
279/
200 promoter region of the
IEX-1 gene.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of p53 on the transcriptional activity
of the IEX-1 promoter in HaCaT cells.
Cells were transiently transfected with a series of
IEX-1 promoter deletion or mutant (mp53/ 279, with the p53
site replaced with a SalI restriction enzyme site)
constructs in the presence (gray bars) and absence
(white bars) of the pCMV-p53 expression vector. The cells
were harvested 24 h later, and a luciferase reporter assay was
performed. pGL3-Basic (which is promoterless) and pGL3-Control
(containing the SV40 enhancer and promoter) were used as negative and
positive controls, respectively. Transfection efficiencies were
normalized to the Renilla luciferase activity from the
cotransfected internal control plasmid (pRL-TK). The activities of the
luciferase reporter are expressed as -fold relative to the activity of
pGL3-Basic (which was assigned an activity value of 1.0). The data
shown are means of three independent experiments in duplicates, with at
least two different plasmid preparations. For detailed experimental
conditions, see "Experimental Procedures."
|
|
Absence of Direct Molecular Cross-talk between p53 and Sp1 in
the Control of IEX-1 Gene Expression--
Based on our findings that
the IEX-1 gene contains transcriptional elements for both
Sp1 and p53, we examined the possibility that these factors may control
IEX-1 gene transcription by molecular cross-talk involving
direct protein/protein interactions. We performed transient
coexpression experiments with p53 and Sp1 and assessed the effects on
IEX-1 promoter activity (reporter construct
279pIEX-1). As shown in Fig.
6, Sp1 enhancement of basal
IEX-1 promoter activity was significantly reduced when the
cellular levels of p53 were elevated by forced expression. This result
is reflected by a 5-fold activation of reporter gene expression by Sp1
in the absence of p53 expression and negligible activation by Sp1 in
the presence of p53 expression (Fig. 6). Mutation of the proximal
Sp1-binding site (bp
63 to
55) near the TATA box, which reduced
basal promoter activity by 70% (Figs. 3 and 4), abolished
Sp1-dependent activation; no p53-mediated suppression of
Sp1 activity was evident. Mutation of the p53-binding site, which
increased the basal promoter activity of the
279pIEX-1
construct, abolished p53-mediated suppression, but did not abrogate
Sp1-dependent activation. The double mutation construct
mp53/mSp1/
279pIEX-1, in which both the Sp1 and p53 elements are mutated, exhibited a very low basal level of transcription that was only severalfold above that observed for the promoterless plasmid pGL3-Basic and showed no response to forced expression of
either Sp1 or p53. Our data indicate that both p53 and Sp1 contribute
to the basal promoter activity of the IEX-1 gene.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 6.
Examination of molecular cross-talk between
the p53 tumor suppressor and Sp1 for the regulation of IEX-1
gene expression. The IEX-1 promoter reporter
construct 279pIEX-1 (white bars) or the
proximal Sp1 site mutant construct mSp1/ 279 was transiently
coexpressed with Sp1 (gray bars) or p53 (black
bars). Coexpression of both factors (Sp1 and p53) is indicated by
hatched bars. The transiently transfected HaCaT cells were
harvested 24 h later, and a luciferase reporter assay was
performed. pGL3-Basic (which is promoterless) and pGL3-Control
(containing the SV40 enhancer and promoter) were used as negative and
positive controls, respectively. Transfection efficiencies were
normalized to the Renilla luciferase activity from the
cotransfected internal control plasmid (pRL-TK). The activities of the
luciferase reporter are expressed as -fold relative to the activity of
the promoterless pGL3-Basic vector (which was assigned an activity
value of 1.0). The data shown are means of three independent
experiments in duplicates, with at least two different plasmid
preparations.
|
|
We performed additional cotransfection experiments by progressively
increasing the amounts of p53 and Sp1 factors and assessed the effects
on IEX-1 promoter activity. As shown in Fig.
7, Sp1-enhanced IEX-1 promoter
activity was significantly reduced to the basal levels observed in the
absence of Sp1 when the cellular levels of p53 were elevated by forced
expression. The reduction of Sp1-dependent promoter
activity corresponded to the amount of p53 that was being overexpressed. Similarly, as concentrations of Sp1 were increased, p53-mediated IEX-1 gene repression was progressively
abolished in an Sp1 concentration-dependent manner (Fig.
7B).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 7.
Effects of increasing amounts of p53 and Sp1
factors on IEX-1 expression. Sp1 or p53 was
cotransfected with IEX-1 promoter
constructs together with gradually increased amounts of p53
(A) or Sp1 (B). The wild-type IEX-1
promoter construct 279pIEX-1 ( ) showed gradual
decreases/increases as the amounts of p53 or Sp1 increased. Mutants of
p53 (mp53/ 279; ) and Sp1 (mSp1/ 279; ) and the double mutant
(mp53/mSp1/ 279; ) were used for cotransfection as controls in this
experiment. The transiently transfected HaCaT cells were harvested
24 h later, and a luciferase reporter assay was performed. The
data shown are means of three independent experiments in duplicates,
with at least two different plasmid preparations.
|
|
We also performed electrophoretic mobility shift assays to investigate
whether p53 and Sp1 interact or interfere with each other through
protein/protein interactions. In vitro translated p53
protein was mixed with increased amounts of in vitro
translated Sp1 protein (1 and 5 µl) in the binding mixture. Increased
amounts of Sp1 protein in the binding mixture did not alter the
formation of p53 protein-DNA complexes (Fig.
8A). Similarly, in
vitro translated Sp1 protein was mixed with increased amounts of
in vitro translated p53 protein (1 and 5 µl) in the
binding mixture. The increased amounts of p53 protein in the binding
mixture did not change the amounts of Sp1 protein-DNA complexes formed
(Fig. 8B). Competition electrophoretic mobility shift assays
using unlabeled specific or nonspecific oligonucleotides showed that
the protein/DNA interactions were sequence-specific (data not shown).
In addition, the mutant oligonucleotides spanning the mutated p53 and
Sp1 sites in the IEX-1 promoter (mutp53/IEX-1 and
mutSp1/IEX-1, respectively) failed to show binding to either
the p53 or Sp1 protein (lane 4). Taken together, these
results demonstrate that the Sp1 and p53 transcription factors do not
interfere with each other's binding to DNA and that ternary complexes
of Sp1/p53 and DNA are not observed. These findings suggest that p53
and Sp1 exert their biological effects independently in the control of
IEX-1 gene expression.

View larger version (48K):
[in this window]
[in a new window]
|
Fig. 8.
p53 and Sp1 binding to cognate DNA response
elements and interactions of p53 and Sp1 proteins in protein-DNA
complex formation. A, in vitro translated
p53 protein was mixed with increased amounts of in vitro
translated Sp1 protein in the presence of the p53 response element of
IEX-1 (p53/IEX-1). The p53 consensus sequence and
p53/IEX-1 demonstrated a similar intensity of protein/DNA
binding, whereas the mutated p53 response element of the
IEX-1 promoter (mutp53/IEX-1) showed no binding.
B, in vitro translated Sp1 protein was mixed with
increased amounts of in vitro translated p53 protein in the
presence of the Sp1 response element of IEX-1
(Sp1/IEX-1). The presence (+) or absence ( ) of the p53 or
Sp1 protein is indicated.
|
|
IEX-1 Gene Expression Is Determined by the Ratio of Sp1 and
p53--
We initiated experiments aimed at understanding how our
cotransfection studies involving p53 and Sp1 in HaCaT cells correspond to the natural stimuli regulating IEX-1 gene expression
through these transcription factors. We determined whether the ratio of p53 and Sp1 was important for the control of IEX-1 gene
expression in vivo. We serum-deprived HaCaT keratinocyte
cells for 3 days; restored normal proliferation by supplementing the
culture medium with serum for 1 and 4 h; and measured the mRNA
expression levels of IEX-1, p53, and Sp1 by Northern
analysis (Fig. 9). The levels of each
mRNA were quantitated and normalized to the mRNA intensity of
GAPDH (Fig. 9, A and B). As shown in Fig.
9A (and plotted after quantitation in Fig. 9B),
an Sp1/p53 ratio <1 (lane 1) was associated with a low
level of IEX-1 mRNA expression. In contrast, Sp1/p53 ratios >1 (expression ratios following serum stimulation for 1 and
4 h were 1.12 and 7.8, respectively) (lanes 2 and
3) were associated with increased amounts of
IEX-1 mRNA. If changes in the Sp1/p53 ratio modulate
IEX-1 gene expression at the transcriptional level, then
serum restoration of cells would be predicted to increase the activity
of the IEX-1 promoter. To test this, we transiently transfected HaCaT cells with the
279pIEX-1 promoter
construct, which contains both p53- and Sp1-binding sites. After
24 h, the transiently transfected HaCaT cells were serum-deprived
for 16 h, followed by serum restoration for 1, 5, and 8 h. As
shown in Fig. 9C, the results of the transient transfections
show a significant increase in IEX-1 promoter activity at
5 h after serum restoration. In contrast, the Sp1-binding site
mutant construct (mSp1/
279) did not exhibit significantly increased
promoter activity following serum restoration. These results are in
agreement with the Northern assays (Fig. 9, A and
B) and support the concept that changes in the Sp1/p53 ratio
regulate IEX-1 gene transcription during serum stimulation.
These results demonstrate that the Sp1/p53 ratio is critical for
IEX-1 gene expression and that these transcription factors
may play a joint role in determining the appropriate expression levels
of IEX-1 to maintain cellular homeostasis and to control cell
growth.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 9.
Relationship between Sp1/p53 mRNA ratios
and expression of IEX-1 following serum replenishment
of HaCaT cells. A, serum-deprived HaCaT cells
(lane 1) and HaCaT cells following serum restoration for
1 h (lane 2) and 4 h (lane 3) were used
to measure the mRNA expression levels of IEX-1, p53, and
Sp1 by Northern analysis. GAPDH was used as internal control for
normalization. B, quantitation of the mRNAs by
PhosphorImager analysis is depicted after normalization to the mRNA
intensity of GAPDH. The Sp1/p53 ratios are shown to the left of the
graph. The highest Sp1/p53 ratio (7.8; lane 3) demonstrated
the highest IEX-1 mRNA intensity, whereas the lowest
Sp1/p53 ratio (0.6; lane 1) corresponded to the lowest
IEX-1 mRNA level. The Sp1/p53 ratios were calculated by
dividing the Sp1 mRNA intensity level by the p53 mRNA intensity
level after quantitation and normalization. C, HaCaT cells
were transiently transfected with the IEX-1 promoter
construct 279pIEX-1, which contains both p53- and
Sp1-binding sites. After 24 h, the transiently transfected HaCaT
cells were serum-deprived for 16 h, followed by serum restoration
for 1, 5, and 8 h. The cells were harvested, and a luciferase
reporter assay was performed. Transfection efficiencies were normalized
to the Renilla luciferase activity from the cotransfected
internal control plasmid (pRL-TK). The activities of the luciferase
reporter are expressed as -fold relative to the activity of pGL3-Basic,
which was assigned an activity value of 1.0.
|
|
 |
DISCUSSION |
In this study, we have shown that the growth-promoting
immediate-early gene IEX-1 is controlled by multiple
regulatory elements in the 5'-region of the gene. These elements are
necessary for maximal IEX-1 promoter activity. Most
interestingly, we found that IEX-1 gene expression is
repressed by the p53 tumor suppressor and activated by the Sp1
transcription factor. Consistent with the multiplicity of regulatory
elements in the IEX-1 promoter, the IEX-1 gene is
regulated by various factors such as x-irradiation (2, 5), ultraviolet
radiation and growth factors (e.g. epidermal growth factor)
(6), steroid hormones (e.g. 1
,25-dihydroxyvitamin D3) (7), 12-O-tetradecanoylphorbol-13-acetate
(5, 6), and inflammatory stimuli (e.g. cytokines, ceramide,
lipopolysaccharide, and lysophosphatidyl- choline) (8). Because
the sequences and functions of cis-acting elements in the
IEX-1 promoter region are highly conserved among different
mammalian species (4, 24), it appears that the complexity of the
IEX-1 promoter evolved to mediate a transcriptional response
under the influence of many distinct types of cell growth-related stimuli.
Our result that p53 represses IEX-1 gene transcription is in
agreement with the biological actions of IEX-1 and its status as a
downstream target gene for the tumor suppressor p53. The biological
actions of IEX-1, which include the induction of cell proliferation and
cell cycle entry, are opposite to the known functions of the p53 tumor
suppressor protein. The p53-mediated repression of IEX-1
transcription suggests a direct mechanism by which p53 may regulate
cell growth in an IEX-1 gene product-dependent manner. Mutations of the p53 tumor suppressor gene are found in a high
percentage of human carcinomas (17, 26, 27). We speculate that
inactivation of p53 in tumor cells prevents repression of IEX-1 gene expression, which is a downstream target gene of
p53. Consequently, genetic inactivation of p53 may result in
up-regulation of IEX-1 expression and stimulation of tumor
cell proliferation. It will be interesting to investigate the
transforming ability of IEX-1 in cells in which p53 is mutated or not expressed.
Schafer et al. (12, 13) have presented data that show
increased IEX-1 promoter activity through protein/DNA
interactions involving p53 (human and rat) and NF-
B (human). Our
data demonstrate that the IEX-1 gene is repressed because
inactivation of the p53-binding site increases basal level
transcription, and forced expression of p53 reduces IEX-1
gene promoter activity. The differences between our present findings
and the observations of Schafer et al. could be due to the
different cell types used in the experiments. In our experiments, we
used the spontaneously immortalized and non-tumorigenic human skin
keratinocyte cell line HaCaT (21), whereas Schafer et al.
used Hep3B, HepG2, 818-4 pancreatic carcinoma, and HeLa cells. In
agreement with cell type-dependent differences in
IEX-1 gene regulation, we found differences in the basal
promoter activity of IEX-1 promoter deletion constructs in
HaCaT cells (this study) compared with results with analogous
constructs transiently transfected in HeLa cells (3). Taken together,
these results suggest that intricate gene regulatory mechanisms may
stringently control differential expression of the IEX-1
gene in different cell types.
Apart from the tumor suppressor p53, which functions as a repressor of
the IEX-1 promoter in HaCaT cells, we found that Sp1, but
not Sp3, is a critical activator of the IEX-1 gene. Sp1
up-regulates IEX-1 promoter activity in a
concentration-dependent manner. The specificity of the
Sp1-induced enhancement of IEX-1 promoter activity is
supported by the absence of a significant increase in transcription following forced expression of Sp3. Deletions and site-directed mutagenesis analysis identified a proximal Sp1 site (bp
63 to
55),
although there are three additional putative Sp1 response elements
located between bp
1419 and
279 of the IEX-1 promoter. Our data indicate that the proximal Sp1 site located between bp
63
and
55 of the IEX-1 promoter region is sufficient for Sp1 responsiveness and mediates a high basal level of transcription. It has
been shown previously that Sp1 and Sp3 can synergize (25, 28) or
cooperate (29) to up-regulate target gene expression. In other cases,
Sp3 has been shown to interfere with Sp1-dependent transcriptional activation by competition with Sp1 for binding to GC
boxes in gene promoters (24, 30, 31). We show here that coexpression of
Sp1 and Sp3 does not result in synergism or repression of Sp1-driven
transcription by Sp3. This finding is similar to that observed for
other cell growth-related genes (e.g. histone H4 and
thymidine kinase) (29) and suggests that Sp1 selectively interacts with
its cognate response element in the IEX-1 promoter.
Several lines of evidence have been reported that indicate
molecular cross-talk between Sp1 and p53, including Sp1/p53-associated reciprocal (32), synergistic (33), and cooperative (34) regulation of
target gene transcription and direct interaction of Sp1/p53
protein-mediated gene activation (33, 35). Bargonetti et al.
(36) have shown that p53 and Sp1 regulate each other's DNA-binding
activity and that this mutual interference modulates transcription from
the human immunodeficiency virus long terminal repeat. The data
presented in this study demonstrate that expression of p53
significantly reduces the Sp1-dependent activation of the IEX-1 gene and that Sp1 inhibits the p53-mediated
suppression of IEX-1 gene expression. Our gel shift assay
showed that neither Sp1 nor p53 interferes with the binding of the
other factor to DNA. These results suggest that the mechanism(s) by
which Sp1 and p53 exert their biological effects on IEX-1
gene expression are independent. Our findings are consistent with the
concept that the ratio of Sp1 and p53 is important for IEX-1
gene expression and that the balance of both gene regulatory proteins
dictates physiological levels of IEX-1 gene expression to
maintain fidelity of cellular homeostasis, cell proliferation, and/or apoptosis.
Schafer et al. (12) observed tumor necrosis
factor-
-induced NF-
B-dependent transactivation via
the NF-
B response element present in the human IEX-1
promoter region in Hep3B cells. In our study, NF-
B did not appear to
play a rate-limiting role in the basal expression of IEX-1
promoter activity in HaCaT cells because the mutation of this putative
site showed only modest reduction of promoter activity (~30%
reduction), and forced expression of I
B
, a dominant-negative
inhibitor of NF-
B, did not show significant changes in
IEX-1 promoter activity. It will be of interest to
investigate whether the NF-
B motif in the IEX-1 promoter mediates gene expression in response to other growth factors or cytokine-related stimuli in HaCaT cells. Although mutation of p300 and
Sox response elements in the IEX-1 promoter reduced reporter gene expression, we did not observe transcriptional effects upon forced
expression of p300 or various Sox factors, including Sox5, Sox6, Sox9,
and Sox18. However, IEX-1 promoter deletion analysis showed
a dramatic decrease in transcriptional activity upon deletion of the
150/
110 segment of the IEX-1 promoter, which contains the putative binding sites for p300, Sox, and NF-
B. Deletion of a
putative E box site (from bp
200 to
150) and an AP4 response element (from bp
110 to
70) resulted in a gradual reduction in
IEX-1 promoter activity. For comparison, mutation of the
proximal Sp1 site (from bp
63 to
55) significantly decreased
IEX-1 promoter activity up to 75~80%, indicating the
critical role of the Sp1 factor in IEX-1 gene expression.
However, a promoter construct containing only the first 70 bp of the
IEX-1 gene promoter exhibited a very modest level of basal
promoter activity. Taken together, these results demonstrate that
multiple gene regulatory elements are present in the IEX-1
promoter region that cooperatively participate in controlling the
physiological levels of IEX-1 gene expression.
In conclusion, we have shown that IEX-1 gene expression is
controlled by the tumor suppressor p53, the transcriptional activator Sp1, and multiple regulatory elements in the promoter of the
IEX-1 gene. Future studies on the biological function of
IEX-1 and the mechanisms that support molecular interactions of IEX-1
in the nucleus should reveal important insights into
IEX-1-dependent control of cell proliferation and responses
to various pharmacological and stress-inducing stimuli.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Research Grants DK25409, DK58546, AR27032, DK59505, and CA015083 (to
R. K.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Mayo Clinic, 911A
Guggenheim, 200 First Street S. W., Rochester, MN 55905. Tel.: 507-284-0020; Fax: 507-266-4710; E-mail: rkumar@mayo.edu.
Published, JBC Papers in Press, February 13, 2002, DOI 10.1074/jbc.M109414200
 |
ABBREVIATIONS |
The abbreviations used are:
NF-
B, nuclear
factor-
B;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
 |
REFERENCES |
| 1.
|
Bravo, R.
(1990)
Semin. Cancer Biol.
1,
37-46[Medline]
[Order article via Infotrieve]
|
| 2.
|
Charles, C. H.,
Yoon, J.-K,
Simske, J. S.,
and Lau, L. F.
(1993)
Oncogene
8,
796-801
|
| 3.
|
Pietzsch, A.,
Buchler, C.,
and Schmitz, G.
(1998)
Biochem. Biophys. Res. Commun.
245,
651-657[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Schafer, H.,
Trauzold, A.,
Siegel, E. G.,
Folsch, U. R.,
and Schmidt, W. E.
(1996)
Cancer Res.
56,
2641-2648[Abstract/Free Full Text]
|
| 5.
|
Kondratyev, A. D.,
Chung, K.,
and Jung, M. O.
(1996)
Cancer Res.
56,
1498-1502[Abstract/Free Full Text]
|
| 6.
|
Kumar, R.,
Kobayashi, T.,
Warner, G. M., Wu, Y.,
Salisbury, J. L.,
Lingle, W.,
and Pittelkow, M. R.
(1998)
Biochem. Biophys. Res. Commun.
253,
336-341[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Kobayashi, T.,
Pittelkow, M. R.,
Warner, G. M.,
Squillace, K. A.,
and Kumar, R.
(1998)
Biochem. Biophys. Res. Commun.
251,
868-873[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Pietzsch, A.,
Buchler, C.,
Asianidis, C.,
and Schmitz, G.
(1997)
Biochem. Biophys. Res. Commun.
235,
4-9[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Schafer, H.,
Lettau, P.,
Trauzold, A.,
Banasch, M.,
and Schmidt, W. E.
(1999)
Pancreas
18,
378-384[Medline]
[Order article via Infotrieve]
|
| 10.
|
Grobe, O.,
Arlt, A.,
Ungefroren, H.,
Krupp, G.,
Rolsch, U. R.,
Schmidt, W. E.,
and Schafer, H.
(2001)
FEBS Lett.
494,
196-200[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Schilling, D.,
Pittelkow, M. R.,
and Kumar, R.
(2001)
Oncogene
20,
7992-7997[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Schafer, H.,
Diebel, J.,
Arlt, A.,
Trauzold, A.,
and Schmidt, W. E.
(1998)
FEBS Lett.
436,
139-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Schafer, H.,
Trauzold, A.,
Sebens, T.,
Deppert, W.,
Folsch, U. R.,
and Schmidt, W. E.
(1998)
Oncogene
16,
2479-2487[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Arlt, A.,
Grobe, O.,
Sieke, A.,
Kruse, M.-L.,
Folsch, U. R.,
Schmidt, W. E.,
and Schafer, H.
(2001)
Oncogene
20,
69-76[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Baker, S. J.,
Markowitz, S.,
Fearon, E. R.,
Willson, J. K.,
and Vogelstein, B.
(1990)
Science
249,
912-915[Abstract/Free Full Text]
|
| 16.
|
Mercer, W. E.,
Shields, M. T.,
Amin, M.,
Sauve, G. J.,
Appella, E.,
Romano, J. W.,
and Ullrich, S. J.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
6166-6170[Abstract/Free Full Text]
|
| 17.
|
Hollstein, M.,
Sidransky, D.,
Vogelstein, B.,
and Harris, C. C.
(1991)
Science
253,
49-53[Abstract/Free Full Text]
|
| 18.
|
El-Deiry, W. S.,
Tokino, T.,
Velculescu, V. E.,
Levy, D. B.,
Parsons, R.,
Trent, J. M.,
Lin, D.,
Mercer, W. E.,
Kinzler, K. W.,
and Vogelstein, B.
(1995)
Cell
75,
817-825
|
| 19.
|
El-Deiry, W. S.,
Harper, J. W.,
O'Connor, P. M.,
Velculescu, V. E.,
Canman, C. E.,
Jackman, J.,
Pietenpol, J. A.,
Burrell, M.,
Hill, D. E.,
and Wang, Y.
(1994)
Cancer Res.
54,
1169-1174[Abstract/Free Full Text]
|
| 20.
|
Poumay, Y.,
and Pittelkow, M. R.
(1995)
J. Invest. Dermatol.
104,
271-276[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Boukamp, P.,
Petrussevska, R. T.,
Breitkreutz, D.,
Hornung, J.,
Markham, A.,
and Fusenig, N. E.
(1988)
J. Cell Biol.
106,
761-771[Abstract/Free Full Text]
|
| 22.
|
Sanger, F.,
Nicklen, S.,
and Coulson, A. R.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
5463-5467[Abstract/Free Full Text]
|
| 23.
|
Im, H.-J.,
Smirnov, D.,
Yuhi, T.,
Raghavan, S.,
Olsson, J. E.,
Muscat, G. E.,
Koopman, P.,
and Horace, H. H.
(2001)
Mol. Pharmacol.
59,
1486-1496[Abstract/Free Full Text]
|
| 24.
|
Birnbaum, M. J.,
van Wijnen, A. J.,
Odgren, P. R.,
Last, T. J.,
Suske, G.,
Stein, G. S.,
and Stein, J. L.
(1995)
Biochemistry
34,
16503-16508[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Ko, J. L.,
Liu, H.-C.,
Minnerath, S. R.,
and Loh, H. H.
(1998)
J. Biol. Chem.
273,
27678-27685[Abstract/Free Full Text]
|
| 26.
|
van Kranen, H. J.,
and de Gruijl, F. R.
(1999)
J. Epidemiol.
9,
S58-S65[Medline]
[Order article via Infotrieve]
|
| 27.
|
Levine, A. J.,
Perry, M. E.,
Chang, A.,
Silver, A.,
Dittmer, D., Wu, M.,
and Welsh, D.
(1994)
Br. J. Cancer
69,
409-419[Medline]
[Order article via Infotrieve]
|
| 28.
|
Gartel, A. L.,
Goufman, E.,
Najmabadi, F.,
and Tyner, A. L.
(2000)
Oncogene
19,
5182-5188[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Huang, L.,
Sowa, Y.,
Sakai, T.,
and Pardee, A. B.
(2000)
Oncogene
19,
5712-5719[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Hagen, G.,
Muller, S.,
Beato, M.,
and Suske, G.
(1994)
EMBO J.
13,
3843-3851[Medline]
[Order article via Infotrieve]
|
| 31.
|
Kwon, H. S.,
Kim, M. S.,
Edenberg, H. J.,
and Hur, M. W.
(1999)
J. Biol. Chem.
274,
20-28[Abstract/Free Full Text]
|
| 32.
|
Li, B.,
and Lee, M. Y.
(2001)
J. Biol. Chem.
276,
29729-29739[Abstract/Free Full Text]
|
| 33.
|
Koutsodonitis, G.,
Tentes, I.,
Papakosta, P.,
Moustakas, A.,
and Kardassis, D.
(2001)
J. Biol. Chem.
276,
29116-29125[Abstract/Free Full Text]
|
| 34.
|
Thornborrow, E. C.,
and Manfredi, J. J.
(2001)
J. Biol. Chem.
276,
15598-15608[Abstract/Free Full Text]
|
| 35.
|
Torgeman, A.,
Mor-Vaknin, N.,
Zelin, E.,
Ben-Aroya, Z.,
Lochelt, M.,
Flugel, R. M.,
and Aboud, M.
(2001)
Virology
281,
10-20[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Bargonetti, J.,
Chicas, A.,
White, D.,
and Prives, C.
(1997)
Cell Mol. Biol.
43,
935-949[Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea